---
title: "Scinai Immunotherapeutics Ltd. (SCNI.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SCNI.US.md"
symbol: "SCNI.US"
name: "Scinai Immunotherapeutics Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T02:03:54.535Z"
locales:
  - [en](https://longbridge.com/en/quote/SCNI.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SCNI.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SCNI.US.md)
---

# Scinai Immunotherapeutics Ltd. (SCNI.US)

## Company Overview

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.scinai.com](https://www.scinai.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: C (0.54)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 175 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 99.24% |  |
| Net Profit YoY | 0.00% |  |
| P/B Ratio | 0.78 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1942206.00 |  |
| Revenue | 1311000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -243.39% | E |
| Profit Margin | -633.64% | E |
| Gross Margin | -202.29% | E |
| Revenue YoY | 99.24% | A |
| Net Profit YoY | 0.00% | C |
| Total Assets YoY | -13.55% | E |
| Net Assets YoY | -18.78% | E |
| Cash Flow Margin | 72.60% | C |
| OCF YoY | 99.24% | A |
| Turnover | 0.10 | E |
| Gearing Ratio | 30.30% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Scinai Immunotherapeutics Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "99.24%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.78",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1942206.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1311000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-243.39%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-633.64%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-202.29%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "99.24%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-13.55%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-18.78%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "72.60%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "99.24%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.10",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "30.30%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.21 | 95/386 | 10.32 | 7.80 | 7.03 |
| PB | 0.71 | 71/386 | 1.33 | 1.05 | 0.50 |
| PS (TTM) | 1.34 | 37/386 | 3.26 | 2.36 | 2.03 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2024-01-03T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.51 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SCNI.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SCNI.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SCNI.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SCNI.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**